M.D. Anderson Cancer Center: Myelodysplastic-Myeloproliferative Diseases trials
The registry lists 10 Myelodysplastic-Myeloproliferative Diseases studies with M.D. Anderson Cancer Center as lead sponsor. 3 are open to participants now and 3 have results posted.
Phase 1 6Phase 2 7No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative NeoplasmRecruitingNCT04140487Phase 1/2
- Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing ChemotherapyRecruitingNCT03630991Phase 1
- Personalized NK Cell Therapy in CBTRecruitingNCT02727803Phase 2
- Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid LeukemiaCompletedNCT02257138Phase 1/2Results posted
- Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or AnemiaCompletedNCT01712308Phase 2Results posted
- Methadone, Morphine, or Oxycodone in Treating Pain in Patients With CancerTerminatedNCT00726830Not applicableResults posted
- Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic SyndromesActive, not recruitingNCT05038592Phase 1/2
- PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT04022785Phase 1
- Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell TransplantActive, not recruitingNCT02861417Phase 2
- Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With MalignanciesWithdrawnNCT01101412Phase 1/2